Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
D001682:Biological Availability; D002220:Carbamazepine / Q000737:chemistry; D002444:Cefuroxime / Q000031:analogs & derivatives* / Q000737:chemistry; D002623:Chemistry Techniques, Analytical; D003461:Crystallography; D003663:Decision Trees; D017277:Drug Approval / Q000379:methods*; D004355:Drug Stability; D016568:Drugs, Generic / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004656:Enalapril / Q000737:chemistry; D006801:Humans; D008968:Molecular Conformation; D044367:Phase Transition; D011224:Prazosin / Q000031:analogs & derivatives* / Q000737:chemistry; D011786:Quality Control; D011899:Ranitidine / Q000737:chemistry; D012995:Solubility; D013449:Sulfonamides / Q000737:chemistry; D013678:Technology, Pharmaceutical; D013810:Therapeutic Equivalency; D000077786:Torsemide; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000737:chemistry
D016568:Drugs, Generic; D013449:Sulfonamides; D002220:Carbamazepine; D014859:Warfarin; D004656:Enalapril; D011899:Ranitidine; C041226:Terazosin; D002444:Cefuroxime; D000077786:Torsemide; D011224:Prazosin; C040738:cefuroxime axetil